|
HIRA expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
9.95670000003557E-07 |
| Normal-vs-Stage3 |
4.44089209850063E-16 |
| Normal-vs-Stage4 |
4.00435240521801E-12 |
| Stage1-vs-Stage2 |
1.291400E-01 |
| Stage1-vs-Stage3 |
4.026400E-02 |
| Stage1-vs-Stage4 |
1.105640E-01 |
| Stage2-vs-Stage3 |
1.065680E-02 |
| Stage2-vs-Stage4 |
2.654200E-02 |
| Stage3-vs-Stage4 |
9.121800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.58859999999095E-05 |
| Normal-vs-Asian |
1.77520220745464E-11 |
| Caucasian-vs-AfricanAmerican |
6.096000E-01 |
| Caucasian-vs-Asian |
6.337200E-01 |
| AfricanAmerican-vs-Asian |
7.999200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.44089209850063E-16 |
| Normal-vs-Female |
1.62470037423645E-12 |
| Male-vs-Female |
8.979800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-15 |
| Normal-vs-Age(61-80Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(81-100Yrs) |
2.584300E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.806400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.549800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.962200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.071500E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.307000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.717400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.48100000000262E-05 |
| Classical-VS-Follicular |
2.012600E-01 |
| Classical-VS-Other |
2.264000E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
5.78079999999925E-05 |
| Tall-VS-Other |
7.859600E-01 |
| Tall-VS-Normal |
1.11022302462516E-16 |
| Follicular-VS-Other |
1.620220E-01 |
| Follicular-VS-Normal |
8.74289973751274E-10 |
| Other-VS-Normal |
2.32449999999496E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.11022302462516E-16 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
3.830700E-04 |
|
|
